PAVM is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-08-13). Three months to 2026-06-30 against 2025-06-30: Revenue $33,000, up 450.0% from $6,000; Net loss $5.4M, 54.8% smaller than $11.9M. Six months to 2026-06-30 against 2025-06-30: Operating cash used $5.3M, 91.5% larger than $2.8M. Read it line by line, each linked to its source → · Every report →
/stocks/PAVM // the workspaceSource: SEC EDGAR · refreshed daily
PAVmed Inc. (PAVM) is a surgical & medical instruments & apparatus company. Piotroski F-Score 2/7. Next earnings projected around 2026-11-12 from PAVM's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
Source: SEC EDGAR · fundamentalsEOD · as of 2026-11-03 close · delayed, not real-time, so no bid or askMarket cap = last close × filed share count. How the count is chosen
why is it moving // cited AI read
What’s behind PAVM’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
CitePAVmed Inc. (PAVM), us-gaap:EarningsPerShareDiluted: -5.63 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001437749-26-010115, filed 2026-03-27. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001624326/us-gaap/EarningsPerShareDiluted.json
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
filings & insider activity // official0 FORM 4 / 90D
newest filing · the five newest 10-K, 10-Q and 8-K filings · SEC EDGAR submissions
8-Kmaterial agreementItem 1.01 reports a material agreement. The summary leaves out terms, so read the agreement if it is attached. Also reports Item 3.03.2026-10-22
8-Kmaterial agreementItem 1.01 reports a material agreement. The summary leaves out terms, so read the agreement if it is attached.2026-09-10
8-Kresults announcedItem 2.02 says results were released, usually in an attached press release. It does not say results improved, and the figures are unaudited. Also reports Item 7.01.press release →2026-08-14
10-Qquarterly reportThe quarterly report. Its statements are reviewed but not audited, and one quarter can mislead on its own.2026-08-13
SourcePiotroski F-Score: nine pass or fail tests on two filed fiscal years
As offiscal year ended 2025-12-31 against 2024-12-31
How2 of the 7 computable tests pass. 2 of 9 cannot be computed from the filings and are not counted as passes or fails. Arithmetic on filed XBRL facts.
As offiscal year ended 2025-12-31 against 2024-12-31; market value at the 2026-11-03 close
How1.2 × working capital / total assets + 1.4 × retained earnings / total assets + 3.3 × EBIT / total assets + 0.6 × market value / total liabilities + 1.0 × sales / total assets = -11.04. Balance sheet and income from the filings; market value is the stored market cap.
quarters ended · through · 12 quarters, as filed · SEC XBRL companyfacts
12 quarters of filed history · red = loss quarter · ★ = biggest revenue growth against the same quarter a year earlier
From PAVM’s quarterly XBRL filings. Fastest revenue growth: the quarter ending Sep 2023 (+941% on a year earlier). Net loss in Sep '22, Mar '23, Jun '23, Sep '23, Mar '24, Jun '24, Jun '25, Sep '25, Mar '26, Jun '26.
loading fair value band…
loading price vs fair value…
loading trailing returns…
loading capital allocation…
loading style box…
loading dividend safety…
loading smart money…
loading classification peers…
loading sic group figures…
loading funds holding…
loading jurisdiction…
fair value // DCF · reverse DCF · Graham — no black boxestimate, not a target
inputs from the fiscal year ended · price close · annual filings, one daily close · SEC XBRL companyfacts and end-of-day bars (Databento)
FAIR-VALUE RANGE
no method had its inputs
CURRENT PRICE
$1.82
TWO-STAGE DCF
not filed
8% growth for 10y, 2.5% terminal, 9% discount
GRAHAM NUMBERiBenjamin Graham's ceiling for a cautious buyer: the highest share price his 1949 rule allows, at 15 times earnings and 1.5 times book value combined. A yardstick, not a forecast.
ASSUMPTION RECEIPTS: YOUR STAGE-1 GROWTH OF 8.0% AGAINST PAVM’S FILED RECORD
Free cash flow per share, realized
3 FILED YEARS
Not computed. Free cash flow per share was negative in fiscal 2022, where this window starts, so a growth rate is not defined.
5 FILED YEARS
Not computed. Free cash flow per share was negative in fiscal 2020, where this window starts, so a growth rate is not defined.
10 FILED YEARS
Not computed. Only 9 consecutive annual reports state it for both years. The report for the fiscal year ending 2016-12-31 does not state operating cash flow, capital expenditure and a diluted share count for both of its years under the concepts read.
Diluted EPS, realized
3 FILED YEARS
Not computed. Diluted EPS was negative in fiscal 2022, where this window starts, so a growth rate is not defined.
5 FILED YEARS
Not computed. Only 3 consecutive annual reports state it for both years. The report for the fiscal year ending 2022-12-31 does not state diluted EPS for both of its years under the concepts read.
10 FILED YEARS
Not computed. Only 3 consecutive annual reports state it for both years. The report for the fiscal year ending 2022-12-31 does not state diluted EPS for both of its years under the concepts read.
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range PAVM has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Plain English for every number above. One AI generation, or free if someone already asked about these numbers.
THE INPUTS — FROM PAVM’S FILINGS, FY ENDING 2025-12-31
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from PAVM’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
revenue // quarterly$33,000
quarters ended · through · 12 quarters, as filed · SEC XBRL companyfacts
2022-09-302026-06-30
net income // quarterly$-5M
quarters ended · through · 12 quarters, as filed · SEC XBRL companyfacts
2022-09-302026-06-30
eps diluted // quarterly$-0.87
quarters ended · through · 12 quarters, as filed · SEC XBRL companyfacts
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as PAVM tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
loading whale holders…
loading co-holdings…
loading institutional holders…
loading equity stakes…
loading insider activity…
loading congress trades…
research brief // the filing-grounded overview + SWOTNEW
A plain-English read on PAVM plus an auto-SWOT, built from PAVM's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
research committee // bull vs bear, from the filingsNEW
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate PAVM using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
ask PAVM // answered from its filing evidence
Ask about PAVM’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
8-Kexecutive or board changeItem 5.02 reports a director or senior officer arriving or leaving, or their pay changing. It seldom says the real reason for a departure. Also reports Item 5.07.2026-06-24
next 14 days // what each source returneda record of what was checked, not a forecast
SEC submissions read · calendar days, the next 14 · the company's own filings on SEC EDGAR, our 8-K date sweep and dates checked by hand
On file for PAVM from Nov 4, 2026 to Nov 17, 2026: earnings date and filing deadline (below).
Event
Result
Source, and when
Earnings date
on file. PAVM reports: Nov 12 (projected from past report dates, not company-confirmed; window Nov 7 to Nov 17; usually before the open, from past SEC filing times). source
the company’s results 8-Ks on EDGAR (the projected window), our sweep of scheduling 8-Ks, and dates checked by hand on company pages; read 2026-11-04
Filing deadline
on file. In the window: the 10-Q for the quarter ending Sep 30, 2026, due 45 days after it for a non-accelerated filer, falls due Nov 16, 2026. Newest periodic report on file: the 10-Q for the period ending Jun 30, 2026, filed Aug 13, 2026. filing list on EDGAR
SEC’s submissions file for the company: its filer status, fiscal year end and newest periodic report; read 2026-11-04
Ex-dividend date
not covered. Not checked. This attestation does not cover ex-dividend dates.
none: we carry no declared ex-dividend dates, only the dividends companies report in their filings
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-04 to 2026-11-17, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
filed figures against its sic group // one metric at a time, no compositemedian and percentile
oldest fiscal year ended · newest fiscal year ended · oldest stored read · newest stored read · one annual report per company, newest on file · SEC XBRL annual reports as our valuation history stored them; SIC descriptions from EDGAR
Group: Surgical & Medical Instruments & Apparatus, the SEC industry code PAVM files under. 9 companies in our stored table file under it.
Metric
PAVM
Group median
25th to 75th percentile
Where PAVM sits
Net marginnet income divided by revenue, same fiscal year
not placed
14.4%⊙
INFERENCE — derived by arithmetic
SourceNet margin across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table
As offiscal years ended 2025-12-31 to 2026-06-30
HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure.
9 companies
12.9% to 23.1%
PAVM has no annual report in the stored table yet, so it has no figure to place.
Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year
not placed
18.2%⊙
INFERENCE — derived by arithmetic
SourceFree cash flow margin across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table
As offiscal years ended 2025-12-31 to 2026-06-30
HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure.
9 companies
9.0% to 29.2%
PAVM has no annual report in the stored table yet, so it has no figure to place.
Return on equitynet income divided by stockholders’ equity at the fiscal year end
not placed
14.5%⊙
INFERENCE — derived by arithmetic
SourceReturn on equity across the 9 companies filing under SEC SIC "Surgical & Medical Instruments & Apparatus" in our stored table
As offiscal years ended 2025-12-31 to 2026-06-30
HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure.
9 companies
9.5% to 23.1%
PAVM has no annual report in the stored table yet, so it has no figure to place.
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
fair value band // not built, 0 of 5 estimators rana range needs 2 estimators
None of the 5 estimators could run on PAVM's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for PAVM. Below is everything that was checked, so the refusal can be read rather than taken on trust.
RAN
Nothing produced a value.
COULD NOT RUN
Median P/E: no price history available.
Median P/S: no price history available.
Median P/B: no price history available.
Median P/FCF: no price history available.
Two-stage DCF: free cash flow is not positive.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for PAVM, so sector medians could not fill the gaps.
feed generated · each disclosure as filed, up to 45 days after the trade · STOCK Act disclosures via the Congress Trading Monitor
No lawmaker has disclosed a trade in PAVM under the STOCK Act.
Volume against its own history: 38% of its last 252 sessions were lighter than the last one, the 2026-11-03 session. End-of-day bars (Databento). Volume detail
last close against its levels // closes, through 2026-11-03
52-week high close12.052026-01-21
200-session average6.51simple, through 2026-11-03
50-session average3.44simple, through 2026-11-03
20-session average2.28simple, through 2026-11-03
Prior close1.912026-11-02
Last close1.822026-11-03
52-week low close0.222025-12-31
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
earnings center PAVM // expectation vs reality
last results 8-K filed · one 8-K per report, closes the session before and after · SEC 8-K Item 2.02 filings and end-of-day bars (Databento)
NEXT REPORT · confidence engine★★★★★HIGH CONFIDENCE~ Nov 12 estUsually before the open, from past SEC filing timesProjected from year-over-year pattern · usually within ~3 days
▸27 historical earnings 8-Ks (Item 2.02) on file
▸Reports on a ~91-day quarterly cadence (+/-4d)
▸Results filed before the open in 7 of the last 8 reports, by EDGAR acceptance time
▸Last report filed 2026-08-14, accepted 10:44 AM ET
Projected from PAVM's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPAVM files or announces.
The BreakdownEARNINGSdeterministic · from filings
PAVM's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Typical move±11.4%
Average move±9.7%
Biggest earnings pop+17.1%
Biggest earnings drop-17.2%
Each figure is one earnings reaction — how much PAVM moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
A more typical earnings reaction has been approximately ±11.4%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
chart read // written by code from end-of-day closes
Recent range
Over the last 20 sessions the close ran from 1.82 on 2026-11-03 to 2.79 on 2026-10-09. The last close, 1.82 on 2026-11-03, sits 0% of the way up that range.
52-week range
The 52-week closing range runs from 0.22 on 2025-12-31 to 12.05 on 2026-01-21. The last close is 84.9% below the high close and 724.3% above the low close.
The window's move
The close changed -32.0% over the last 20 sessions. Of the 568 earlier 20-session windows on file since 2024-07-01, 82% were smaller in size, up or down. Over 63 sessions it changed -63.9%.
Averages
The last close is 47.1% below its 50-session average of 3.44 and 72.1% below its 200-session average of 6.51. The 50-session average sits 47.2% below the 200-session average.
Largest daily moves
The largest close-to-close moves of the last 63 sessions: -26.8% on 2026-10-01, -13.3% on 2026-10-14, +12.6% on 2026-08-13.
Daily range
Wilder's ATR over 14 sessions is 13.39% of the close. Its median over the last 252 sessions was 10.12%.
Volume
Volume on 2026-11-03 was 12,604 shares, 1.10 times the average of the 20 sessions before it. The last 20 sessions averaged 0.03 times the average of the last 252.
RSI (14)
Wilder's RSI over 14 sessions reads 24.4 on a scale of 0 to 100.
+1.9%
▲Bullish
2024-11-14
+11.8%
▲Bullish
Resistance areas
The nearest resistance area our tool finds above the last close spans 1.87 to 1.93, 2.7% above. 3 sessions traded up into it and closed below it. It was last traded in on 2026-11-03. Measured on 136 tickers (2026-10-05), the nearest such area held, with no close above it for 5 sessions, 33.4% of the times it was reached within 20 sessions, against 33.3% for random bands of the same width: no measured edge.
Daily closes from 2024-07-01 through 2026-11-03, 589 sessions, split-adjusted. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in PAVM’s filings; the chart with studies draws every figure.
Written by code from 589 end-of-day bars through 2026-11-03. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
AI writes the read above in plainer words, from those figures only. 1 generation (Pro), or free if someone already asked about the 2026-11-03 read.
oldest 13F quarter ended · newest · quarterly, filed up to 45 days after the quarter · each fund's latest SEC Form 13F-HR
No tracked institution reported a position in PAVM in the latest 13F round.
insider activity PAVM // Form 4, open-marketFULL TRACKER →
no as-of date carried by this data · each Form 4 as filed, open-market trades over about six months · SEC Form 4 filings
No open-market Form 4 buys or sells reported for PAVM in the last ~6 months.
what is new on file for PAVM // four checks, each datedwhat was checked, not a judgement
congress feed generated · short interest settlement · four checks, each over 30 days back from its own source date · SEC EDGAR, Form 4, STOCK Act disclosures and FINRA short interest
2 of the 2 checks that ran found nothing new for PAVM. 2 could not run.
Filings
NOT CHECKED
Newest 10-K, 10-Q or 8-K on record: the 8-K (material agreement) filed 2026-10-22. When this list was stored is not recorded for this company, so no "nothing since" claim is made.all filings →
Insider trades
NOT CHECKED
The Form 4 list for this company was read from source for this page build and that read time is not recorded, so no window claim is made. The insider panel below shows what was found.insider panel →
Congress trades
NOTHING NEW
No STOCK Act disclosure of a trade filed in the 30 days to 2026-11-04. None is on record in the feed. Members of Congress disclose a trade up to 45 days after it happens.⊙
EVIDENCE — filed/published fact
SourceSTOCK Act disclosures (House Clerk, Senate eFD), via the Congress Trading Monitor
As of2026-11-04 (feed generated)
HowDates are filing dates as disclosed. Trades are reported up to 45 days after they happen.
12,717 shares short at the 2026-10-15 settlement, inside the range of the 24 settlements in the 12 months before it (7,939 to 1,130,869, from 2025-10-15).⊙
INFERENCE — derived by arithmetic
SourceFINRA consolidated short interest, biweekly archive
FieldcurrentShortPositionQuantity
As of2026-10-15 settlement
HowThe latest settlement against the lowest and highest of the 24 settlements in the 12 months before it. Arithmetic on FINRA's figures; not split-adjusted.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Where PAVM is incorporated // the company’s own filing
10-Q cover filed · checked · as of the latest periodic report cover · the company's own report cover, EDGAR's directory as a cross-check
Incorporated in Delaware, United States
Head office: New York, New York, United States · the company’s charter and its head office are in different states.
Source: the cover page of PAVmed Inc.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-11-04. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works